# Allocetra-OTS in COVID-19, Phase II

> **NCT04590053** · PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 24 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Allocetra-OTS

## Key facts

- **NCT ID:** NCT04590053
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-20
- **Primary completion:** 2021-02
- **Final completion:** 2021-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590053, "Allocetra-OTS in COVID-19, Phase II". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04590053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*